Glenmark Pharmaceuticals has received final approval for Tacrolimus ointment, from the US health regulator. The ointment is used for treating atopic dermatitis (eczema).

In a BSE filing the company stated, Glenmark Pharmaceuticals Inc USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Tacrolimus ointment USP, 0.1%. The ointment is a generic version of Protopic ointment, of Leo Pharma AS in the same strength.

Further, the company has 132 products authorized for distribution in the US market and 61 Abbreviated New Drug Applications (ANDA’s) pending approval with the USFDA.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for The Week